Hypokalemia in heart failure: A low or a high point?

Aldahl M Jensen A-SC Davidsen L , et al. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 2017; 38: 2890–2896.

Ponikowski P Voors AA Anker SD , et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.

Urso C Brucculeri S Caimi G. Acid-base and electrolyte abnormalities in heart failure: Pathophysiology and implications. Heart Fail Rev 2015; 20: 493–503.

Huang C-L Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol 2007; 18: 2649–2652.

Osadchii OE. Mechanisms of hypokalemia-induced ventricular arrhythmogenicity. Fundam Clin Pharmacol 2010; 24: 547–559.

Ahmed A Zannad F Love TE , et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007; 28: 1334–1343.

Collins AJ Pitt B Reaven N , et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol 2017; 46: 213–221.

Núñez J Bayés-Genís A Zannad F , et al. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation 2018; 137: 1320–1330.

Aldahl M Polcwiartek C Davidsen L, et al. Short-term prognosis of normalising serum potassium following an episode of hypokalaemia in patients with chronic heart failure. Eur J Prev Cardiol 2020, epub ahead of print, DOI: 10.1177/2047487320911154.

Zannad F McMurray JJV Krum H , et al. Eplerenone in patients with systolic heart failure and mild symptoms. New Engl J Med 2010; 364: 11–21.

Vardeny O Claggett B Anand I , et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014; 7: 573–579.

Pfeffer MA Claggett B Assmann SF , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34–42.